Overview
Immunotherapy has changed how cancer is treated, although response rates remain low due in part to resistance mechanisms concentrated within the tumor microenvironment. In this seminar, Greg Delgoffe will discuss how the metabolic features of the tumor microenvironment can shape T cell differentiation to alternative fates, and highlight how metabolic reprogramming can be harnessed to promote superior antitumor immunity.
This webinar is supported by: Thermo Fisher Scientific
The production of this webinar was supported by Thermo Fisher Scientific. Thermo Fisher Scientific has had no influence on the content, and full editorial control remains the sole responsibility of IUIS.
Thermo Fisher Scientific understands your samples are precious in immunology research. Our products and technologies support your wise use of samples to get qualitative and quantitative measurements when evaluating experiments. Our mission is to enable our customers to make the world healthier, cleaner, and safer.
Speakers
Greg Delgoffe
Greg M. Delgoffe is Associate Professor of Immunology at the University of Pittsburgh, and Director of the Tumor Microenvironment Center at the UPMC Hillman Cancer Center. Dr. Delgoffe obtained his Ph.D at Johns Hopkins School of Medicine in 2010, and completed postdoctoral training at St. Jude Children’s Research Hospital. Since its inception in 2014, Delgoffe’s lab has worked to both understand the metabolic deficiencies experienced by T cells as they infiltrate tumors and leverage that insight into metabolic strategies to bolster antitumor immunity. His group has shown metabolic defects are central to T cell dysfunction in cancer, suggesting all forms of immune-based therapy may be improved by metabolic modulation.
Wendy Burgers
Wendy Burgers is an Associate Professor and Member of the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town (UCT), South Africa. She has a PhD from the University of Cambridge, and is a Senior Fellow of the European and Developing Countries Clinical Trials Partnership (EDCTP). For the past 2 years her research group has studied T cell responses to SARS-CoV-2 infection and vaccination. Dr Burgers leads the Cellular Immunology subgroup of the South African National Variant Consortium, and is a member of the Ministerial Advisory Committee on COVID vaccines. She also teaches infectious disease immunology to undergraduates at UCT.
Webinar Details
Categories: None
